Moderna's Patent Fortress Has No Walls. What It Has Is Harder to Copy.

In February 2022, a company most people had never heard of — Genevant, backed by Arbutus Biopharma — sued the most famous biotech on earth for infringing six patents in the manufacture of the very vaccine that had made Moderna a household name.⁴ Moderna fought to have those patents thrown out. It largely lost.⁴ Four years later it wrote a check for $2.25 billion to make the case go away.³ The settlement included something telling: a license for Moderna to keep using the lipid technology going forward.³ You do not pay for a license to something you already own.

The official story is that Moderna sits behind an impregnable mRNA patent fortress — it owns the science, it sued Pfizer to prove it, and everyone else is a trespasser. The real story is the inverse. Moderna's patents are being contested from three directions at once, the molecule everyone calls its secret sauce is documented in public, and the one thing protecting the company turns out to be the thing no court can adjudicate.

Three flanks, all of them exposed

A moat is supposed to surround you. Moderna's is breached on every side. Start with the shell. Every mRNA vaccine needs a lipid nanoparticle — a microscopic fatty bubble — to carry the fragile genetic instructions into your cells. Moderna did not invent the foundational version of that bubble. Arbutus and Genevant did, patented it, and sued.⁴ When Moderna tried to invalidate those patents at the patent office, it was, in the words of Arbutus's own filing, largely unsuccessful — and the dispute ended in a $2.25 billion settlement and a license back to the technology.³ That is not a company defending a moat. That is a company renting the drawbridge.

The second flank is the vaccine sequence itself. The U.S. government's vaccine institute argued that leaving NIH scientists off the principal patent application 'deprives NIH of a co-ownership interest,' and the NIH director called it 'a serious mistake.'⁶ Moderna's reply was confident — its scientists chose the sequence and NIH researchers 'were not even aware of the mRNA sequence' until after filing.⁶ But then, in September 2021, Moderna offered to make the U.S. government a co-owner of the applications listing only its own scientists.⁶ You do not offer to share what you are certain is yours alone. The offer is the tell: the question of who invented the vaccine is open, not closed.

The third flank is the one Moderna chose to fight on. In August 2022 it sued Pfizer and BioNTech for infringement, asserting three patents with priority dates between 2011 and 2016.⁵ The counter-move was surgical: Pfizer and BioNTech took those patents to the USPTO's review board, called them 'unimaginably broad,' and the patent office paused Moderna's lawsuit to re-examine the patents it was suing over.⁵ By September 2025, a Markman ruling — the judge's interpretation of what the patents actually cover — came down in Pfizer and BioNTech's favor.⁵ Moderna went to war to prove the fortress was real and ended up watching its own walls get measured by the other side.

The secret sauce is on Wikipedia

Defenders of the fortress thesis point to SM-102 — the ionizable lipid at the heart of Spikevax — as the proprietary jewel nobody can copy. But SM-102's chemical structure is not a trade secret. It was first described in a Moderna patent application in 2017 and a published study in 2018, its structure and synthesis pathway are documented in the chemistry press, and the molecule is now sold by third-party suppliers.⁷ Pfizer and BioNTech didn't even need it; they licensed a structurally similar lipid, ALC-0315, from Acuitas and built a competing vaccine.⁷ If a competitor can buy your jewel from a catalogue or substitute a near-twin, it was never the moat. The molecule is published. What isn't published is how to make it at scale, reliably, billions of doses at a time — Moderna discloses that it has proprietary LNP manufacturing processes for particle assembly and purification, but not the parameters that make them work.⁸ The know-how, not the molecule, is the part that stays behind the wall.

What the lawsuits can't touch

So what actually protects Moderna? Strip away the contested patents and what remains is harder to litigate and harder to copy: a decade of running the same platform over and over, and a pipeline deep enough to absorb the failures. Moderna spent $4.5 billion on R&D in 2024 alone.¹ It reports the largest late-stage pipeline of mRNA medicines in the world — 45 programs, 2 approved medicines, 7 candidates in Phase 3 — and management claims a mid- and late-stage success probability of roughly 69% against an industry average near 19%.⁹ Take those numbers as the company's own framing, not gospel. But the shape of the argument holds: a rival can license SM-102 and read the patents, and still not know what Moderna learned by manufacturing billions of doses under emergency conditions. That experience is not a document. It cannot be subpoenaed, and it cannot be designed around.

Isn't a deep pipeline just a richer way to lose?

The honest objection is that 'accumulated experience' is the moat companies claim when they can't find a real one — and the numbers do not flatter the thesis. Moderna's revenue went from $19.3 billion in 2022 to $6.8 billion in 2023 to roughly $3 billion in 2024, all of it now a single product, Spikevax.¹² And the company itself attributes the decline not only to a fading pandemic but to 'lower vaccination rates and increased market competition.'² In 2024 it wrote down $495 million of inventory it couldn't sell and paid $155 million in third-party royalties on the science it does use.² A platform that hemorrhages five-sixths of its revenue in two years and pays rent on its own delivery system does not look invincible. Fair. But notice what the collapse does not threaten: the pipeline kept advancing, the R&D kept compounding, and the manufacturing knowledge kept accruing while the COVID windfall evaporated. The pandemic was the revenue. The platform is the bet. A moat is not whether you're winning today — it's whether the next product is cheaper for you to make than for anyone else to start. On that test, the experience is real even when the revenue isn't.

Moderna's mistake was believing its own press: that it owned mRNA the way Coca-Cola owns its formula. It doesn't. It rented the lipid shell, it's still arguing over who invented the sequence, and its broadest patents are being read narrowly by a court. The fortress everyone pictures is a litigation map with holes on every flank. The real protection was never the thing it kept suing over. It was the thing it could never have written down — and the moment to see that clearly is now, while the lawyers are still billing for the part that was never the moat at all.